Small RNA sequencing to differentiate lung squamous cell carcinomas from metastatic lung tumors from head and neck cancers.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Circulating MicroRNA*/blood ; Circulating MicroRNA*/genetics ; Head and Neck Neoplasms*/blood ; Head and Neck Neoplasms*/classification ; Head and Neck Neoplasms*/genetics ; Lung Neoplasms*/blood ; Lung Neoplasms*/classification ; Lung Neoplasms*/genetics ; RNA, Neoplasm*/blood ; RNA, Neoplasm*/genetics ; RNA-Seq* ; Squamous Cell Carcinoma of Head and Neck*/blood ; Squamous Cell Carcinoma of Head and Neck*/classification ; Squamous Cell Carcinoma of Head and Neck*/genetics; Aged ; Aged, 80 and over ; Female ; Humans ; Male
    • Abstract:
      Distinguishing lung squamous cell carcinoma (LSQCC) from a solitary metastatic lung tumor (MSQCC) from head and neck squamous cell carcinoma (HNSQCC) presents a difficult diagnostic challenge even after detailed pathological assessment. Treatment options and estimated survival outcomes after pulmonary resection differ between patients with LSQCC and MSQCC. This study aimed to investigate whether microRNA (miRNA) profiling by RNA sequencing of HNSQCC, MSQCC, and LSQCC was useful for differential diagnosis of MSQCC and LSQCC. RNA sequencing was performed to identify bioinformatically significant miRNAs from a formalin-fixed paraffin-embedded (FFPE) block from a derivation set. MiRNA levels were confirmed by validation sets using FFPE samples and serum extracellular vesicles from patients. Step-wise discriminant analysis and canonical discriminant analysis identified 13 miRNAs by which the different expression patterns of LSQCC, MSQCC, and HNSQCC groups were demonstrated. Six miRNAs (miR-10a/28/141/320b/3120) were assessed in validation sets, and 4 miRNAs (miR-10a/28/141/3120) were significantly upregulated in LSQCCs compared with MSQCCs and HNSQCCs. Serum extracellular vesicles from LSQCC patients demonstrated significantly elevated miR-10a (p = .042), miR-28 (p = .041), and miR-3120 (p = .047) levels compared with those from MSQCC patients. RNA sequencing is useful for differential diagnosis of LSQCC and MSQCC, and the expression level of miR-10a, miR-28, and miR-3120 in serum extracellular vesicles are promising noninvasive tools for this purpose.
      Competing Interests: The authors have declared that no competing interests exist.
    • References:
      Gen Physiol Biophys. 2019 Nov;38(6):525-533. (PMID: 31829310)
      Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3794-9. (PMID: 19234131)
      Biochem Biophys Res Commun. 2018 Feb 5;496(2):302-308. (PMID: 29307822)
      J Cell Biol. 2013 Feb 18;200(4):373-83. (PMID: 23420871)
      Signal Transduct Target Ther. 2016 Jan 28;1:15004. (PMID: 29263891)
      Front Oncol. 2014 May 27;4:127. (PMID: 24904836)
      J Thorac Cardiovasc Surg. 1996 Apr;111(4):827-31; discussion 832. (PMID: 8614143)
      Blood. 2015 Aug 27;126(9):1106-17. (PMID: 26100252)
      Int J Clin Exp Pathol. 2019 Feb 01;12(2):559-567. (PMID: 31933860)
      Nat Cell Biol. 2015 Jun;17(6):816-26. (PMID: 25985394)
      Int J Cancer. 2005 Oct 10;116(6):963-71. (PMID: 15880414)
      Anticancer Res. 2017 Aug;37(8):4345-4352. (PMID: 28739727)
      Cells. 2020 Feb 03;9(2):. (PMID: 32028704)
      Nat Rev Immunol. 2002 Aug;2(8):569-79. (PMID: 12154376)
      Int J Clin Exp Pathol. 2018 Feb 01;11(2):773-780. (PMID: 31938164)
      J Cell Commun Signal. 2020 Jun;14(2):233-244. (PMID: 32034654)
      Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004. (PMID: 14973191)
      Cancer Cell Int. 2019 Sep 27;19:248. (PMID: 31572065)
      Clin Cancer Res. 2005 Sep 15;11(18):6608-14. (PMID: 16166439)
      J Natl Cancer Inst. 1998 Jul 1;90(13):972-7. (PMID: 9665144)
      Clin Exp Immunol. 2017 Sep;189(3):259-267. (PMID: 28369805)
      Clin Imaging. 2015 Sep-Oct;39(5):735-49. (PMID: 26117564)
      J Thorac Cardiovasc Surg. 2017 Aug;154(2):714-727. (PMID: 28495058)
      Biochim Biophys Acta. 2012 Jul;1820(7):940-8. (PMID: 22503788)
      J Mol Med (Berl). 2013 Apr;91(4):431-7. (PMID: 23519402)
      Nat Rev Immunol. 2009 Aug;9(8):581-93. (PMID: 19498381)
      Genomics Proteomics Bioinformatics. 2015 Feb;13(1):17-24. (PMID: 25724326)
      Genes (Basel). 2019 Oct 28;10(11):. (PMID: 31661871)
      Mol Ther Nucleic Acids. 2018 Mar 2;10:131-141. (PMID: 29499928)
      Nat Med. 2012 Jun;18(6):883-91. (PMID: 22635005)
      Cell Death Dis. 2017 Apr 6;8(4):e2739. (PMID: 28383561)
      Oncotarget. 2016 Aug 23;7(34):54852-54866. (PMID: 27363026)
      J Cell Biochem. 2019 Apr;120(4):4987-4997. (PMID: 30302800)
    • Accession Number:
      0 (Circulating MicroRNA)
      0 (RNA, Neoplasm)
    • Publication Date:
      Date Created: 20210305 Date Completed: 20211011 Latest Revision: 20211011
    • Publication Date:
      20231215
    • Accession Number:
      PMC7935561
    • Accession Number:
      10.1371/journal.pone.0248206
    • Accession Number:
      33668046